CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway

BACKGROUND: Cisplatin (DDP) is standard-of-care and first-line management for ovarian cancer (OvCa). Circular RNA HIPK2 (circHIPK2) is abnormally upregulated in serum of OvCa patients. However, its role in DDP resistance remains unclear. METHODS: Expression of cirHIPK2, microRNA (miR)-338-3p and chr...

Full description

Saved in:
Bibliographic Details
Published in:Onco Targets Ther
Main Authors: Cao, Yang, Xie, Xin, Li, Mingzhu, Gao, Yuhua
Format: Artigo
Language:Inglês
Published: Dove 2021
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128508/
https://ncbi.nlm.nih.gov/pubmed/34012271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S291823
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items